PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients

被引：0
|
作者：
Ming Chen
Jinlian Zhu
Xuedong Yang
Jianxin Yao
Yuqing Liu
Qiang Liu
机构：
[1] Changshu No.2 People’s Hospital,Department of Hematology
[2] Changshu No.2 People’s Hospital,Department of Oncology
[3] Changshu No.1 People’s Hospital,Department of Hematology
来源：
European Journal of Medical Research | / 27卷
关键词：
Relapsed/refractory multiple myeloma; T cell subtype; PD-1; LAG-3;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma
    Cornell, Robert Frank
    Baz, Rachid
    Richter, Joshua R.
    Rossi, Adriana
    Vogl, Dan T.
    Chen, Christine
    Shustik, Chaim
    Alvarez, Mariano J.
    Shen, Yao
    Unger, T. J.
    Ben-Shahar, Osnat
    Wang, Hongwei
    Baloglu, Erkan
    Senapedis, William
    Ma, Xiwen
    Landesman, Yosef
    Bai, Xiang
    Bader, Justin
    Xu, Hongmei
    Marshall, Tracey
    Chang, Hua
    Walker, Christopher J.
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Hofmeister, Craig C.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (02) : E54 - E58
  • [22] Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients
    Ye, J. Christine
    Chen, Liying
    Chen, Jason
    Parkin, Brian
    Polk, Avery
    Kandarpa, Malathi
    Cole, Craig E.
    Campagnaro, Erica L.
    Robinson, Dan
    Wu, Yi-Mi
    Talpaz, Moshe
    Yesil, Jennifer
    Auclair, Daniel
    Bergsagel, P. Leif
    Chinnaiyan, Arul
    Baladandayuthapani, Veerabhadran
    BLOOD, 2019, 134
  • [23] Salvage therapies and clinical outcomes after relapse following BCMA CAR-T in patients with relapsed/refractory multiple myeloma
    Reyes, Kevin
    Liu, Yen-Chun
    Huang, Chiung-Yu
    Banerjee, Rahul
    Martin, Thomas
    Shah, Nina
    Wong, Sandy
    Wolf, Jeffrey
    Arora, Shagun
    Chung, Alfred
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S31 - S32
  • [24] Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Jung, Sung-Hoon
    Lee, Seung-Shin
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [25] Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab
    Chari, Ajai
    Krishnan, Amrita
    Rasche, Leo
    Ye, Jing Christine
    Garfall, Alfred
    Popat, Rakesh
    Lipe, Brea
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara
    Tomlinson, Chalmer
    Hilder, Brandi
    Tolbert, Jaszianne
    Renaud, Thomas
    Smit, M. Damiette
    Gray, Kathleen
    Kane, Colleen
    Heuck, Christoph
    van de Donk, Niels W. C. J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10): : 665 - +
  • [26] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Song Mu
    Yoshiaki Kuroda
    Hirohiko Shibayama
    Masayuki Hino
    Takeshi Tajima
    Claudia Corrado
    Rong Lin
    Edward Waldron
    Florence Binlich
    Kenshi Suzuki
    European Journal of Clinical Pharmacology, 2016, 72 : 153 - 161
  • [27] Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
    Mu, Song
    Kuroda, Yoshiaki
    Shibayama, Hirohiko
    Hino, Masayuki
    Tajima, Takeshi
    Corrado, Claudia
    Lin, Rong
    Waldron, Edward
    Binlich, Florence
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 153 - 161
  • [28] Predictors Of Survival Outcomes In Phase I Relapsed Or Refractory Multiple Myeloma Patients
    Harvey, R. Donald
    Barbee, Meagan S.
    Nooka, Ajay K.
    Kim, Sungjin
    Chen, Zhengjia
    Heffner, Leonard T.
    Kaufman, Jonathan L.
    Lonial, Sagar
    BLOOD, 2013, 122 (21)
  • [29] Racial differences in outcomes of patients with relapsed/refractory multiple myeloma treated with selinexor
    Cole, Craig
    Opalikhin, Anne Maria
    McCartney, Matthew
    Heideman, Caroline
    Pentapati, Swetha
    Wang, Ling
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma
    Biran, Noa
    Vesole, David H.
    Zhang, Shijia
    Richter, Joshua R.
    Kuo, Yen-Hong
    Schmidt, Linda
    McBride, Laura
    Anand, Palka
    Ivanovski, Kristin
    Pierre, Amy
    Kumka, Susan
    Cuccurullo, Carmela
    Siegel, David S.
    BLOOD, 2016, 128 (22)
12345